BMY Jan 2026 62.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 10:21AM EDT. Market open.
| Previous Close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.8900 |
| Ask | 1.6400 |
| Strike | 62.50 |
| Expire Date | 2026-01-16 |
| Day's Range | 0.8000 - 0.8000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 337 |
Business WireBristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
PRINCETON, N.J., June 03, 2024--BMS' Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
Business WireBristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
Business WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
© 2024 Yahoo. All rights reserved.